

Effectiveness of Prophylactic Surgeries in *BRCA1* or *BRCA2* Mutation Carriers: A Meta-analysis and Systematic Review

Xiao Li^{1,2}, Ran You³, Xinwei Wang⁴, Congxin Liu⁵, Zicheng Xu¹, Jin Zhou¹, Bin Yu¹, Ting Xu¹, Hongzhou Cai¹, and Qing Zou¹

Abstract

Purpose: To systematically investigate the effectiveness of prophylactic surgeries (PS) implemented in women carrying *BRCA1/2* mutations.

Experimental Design: The PubMed database was searched till August 2014 and 15 studies met the inclusion criteria. Fixed- or random-effects models were conducted according to study heterogeneity. We calculated the pooled relative risks (RR) for cancer risk or mortality along with 95% confidence intervals (CI).

Results: Prophylactic bilateral salpingo-oophorectomy (BSO) and bilateral prophylactic mastectomy (BPM) were both associated with a decreased breast cancer risk in *BRCA1/2* mutation carriers (RR, 0.552; 95% CI, 0.448–0.682; RR, 0.114; 95% CI, 0.041–0.317, respectively). Similar findings were observed in *BRCA1* and *BRCA2* mutation carriers separately. Moreover, con-

tralateral prophylactic mastectomy (CPM) significantly decreased contralateral breast cancer incidence in *BRCA1/2* mutation carriers (RR, 0.072; 95% CI, 0.035–0.148). Of note, BSO was associated with significantly lower all-cause mortality in *BRCA1/2* mutation carriers without breast cancer (HR, 0.349; 95% CI, 0.190–0.639) and those with breast cancer (HR, 0.432; 95% CI, 0.318–0.588). In addition, all-cause mortality was significantly lower for patients with CPM than those without (HR, 0.512; 95% CI, 0.368–0.714). However, BPM was not significantly associated with reduced all-cause mortality. Data were insufficient to obtain separate estimates of survival benefit with PS in *BRCA1* or *BRCA2* mutation carriers.

Conclusions: *BRCA1/2* mutation carriers who have been treated with PS have a substantially reduced breast cancer incidence and mortality. *Clin Cancer Res*; 22(15); 3971–81. ©2016 AACR.

Introduction

Women, who carry a deleterious mutation in breast cancer susceptibility gene 1 (*BRCA1*) or breast cancer susceptibility gene 2 (*BRCA2*), have a high lifetime risk of developing breast cancer, clearly above the risk for the general population. By the age of 70 years, the breast cancer risk is 40% to 80% for *BRCA1* or *BRCA2* mutation carriers (1, 2). Besides, women with *BRCA1* or *BRCA2* mutation and a history of primary breast cancer (PBC) have a significantly elevated risk of developing contralateral breast cancer

(CBC). The estimated cumulative lifetime risk of CBC is 20% to 83% for *BRCA1/2* mutation carriers (3–7).

BRCA1/2 mutation carriers are advised to consider different risk-reducing strategies, including surveillance (breast self-examination, clinical breast examination, screening using mammography and breast magnetic resonance imaging), chemoprevention and prophylactic surgery (8). However, the risk-reducing methods vary in their effectiveness. For about 20 years, researchers have studied whether prophylactic surgery can reduce the cancer and mortality risk in *BRCA1/2* mutation carriers.

Prophylactic mastectomy (PM) implies either a bilateral prophylactic mastectomy (BPM) in high-risk unaffected women or a contralateral prophylactic mastectomy (CPM) after a unilateral therapeutic mastectomy. It has been demonstrated that BPM is a highly effective strategy to reduce the risk of breast cancer at high risk (9, 10). CPM is also considered to be the most effective option for CBC risk reduction (11, 12). However, the ultimate goal of PM is to improve survival, eventually being the reason for a woman to decide for this drastic intervention. A prospective cohort study carried out by Heemskerk-Gerritsen and colleagues (13) showed that after BPM, all-cause mortality and breast cancer-specific mortality rates were reduced, compared with surveillance, but significant survival benefits could not be claimed. On the other hand, data on survival of PBC patients with *BRCA1/2* mutation who opt for subsequent CPM were inconsistent. Some studies showed improved survival after CPM (14, 15), while others did not (11, 16).

Prophylactic bilateral salpingo-oophorectomy (BSO) has also been shown to reduce breast cancer risk in mutation

¹Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China. ²Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. ³Department of Intervention, Affiliated Hospital of Nantong University, Nantong, China. ⁴Department of Oncology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China. ⁵Department of General Surgery, Zhongda Hospital Affiliated to Southeast University, Nanjing, China.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

X. Li, R. You, and X. Wang contributed equally to this article.

Corresponding Authors: Hongzhou Cai, Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, 42 Baiziting Road, Nanjing 210009, China. Phone: 8615950539694; Fax: 8602583780079; E-mail: caihongzhou@njmu.edu.cn; and Qing Zou, Phone: 8613905173337, zouqing_urology@sina.com

doi: 10.1158/1078-0432.CCR-15-1465

©2016 American Association for Cancer Research.

Translational Relevance

This report compiles data from 15 studies independently. In this article, we identified that prophylactic bilateral salpingo-oophorectomy (PBSO) and bilateral prophylactic mastectomy (BPM) were both associated with a decreased breast cancer risk in breast cancer susceptibility gene 1 (*BRCA1*) or breast cancer susceptibility gene 2 (*BRCA2*) mutation carriers. Similar findings were observed in *BRCA1* and *BRCA2* mutation carriers separately. Moreover, contralateral prophylactic mastectomy (CPM) significantly decreased contralateral breast cancer incidence in *BRCA1/2* mutation carriers. Notably, PBSO was associated with significantly lower all-cause mortality in *BRCA1/2* mutation carriers without breast cancer and those with breast cancer. In addition, all-cause mortality was significantly lower for patients with CPM than those without. However, BPM was not significantly associated with reduced all-cause mortality. The results could be utilized by health care professionals.

carriers. According to the National Comprehensive Cancer Network guidelines, PBSO is recommended for all *BRCA1/2* mutation carriers by age 35 to 40 or once childbearing is complete. However, the reported efficacy of PBSO in reducing the risk of breast cancer has varied widely, from 38% to 72% (17–21). It has also been suggested that the effect of PBSO differs between *BRCA1* and *BRCA2* mutation carriers. Eisen and colleagues (17) demonstrated that PBSO may be associated with a lower breast cancer risk in *BRCA1* mutation carriers than that in *BRCA2* mutation carriers (56% vs. 43%). While Kauff and colleagues (20) observed a statistically significant breast cancer risk reduction following PBSO in *BRCA2* but not *BRCA1* mutation carriers.

Although some studies showed that PBSO reduced the risk of breast cancer significantly, that such risk reduction translated into a mortality benefit cannot be assumed. Ingham and colleagues (22) demonstrated that the hazard of death was statistically significantly lower following PBSO versus no PBSO. The 10-year survival rate for women having PBSO was 98.9% among *BRCA1* and 98.0% among *BRCA2* carriers. A large previous multicenter cohort study (PROSE) also demonstrated an improvement in survival for PBSO (23). However, mortality reduction estimates for women with and without a prior history of breast cancer may differ. PBSO in a study carried out by Evans and colleagues (16), improved breast cancer patients' survival significantly. While Metcalfe and colleagues (15) demonstrated that PBSO was not associated significantly with reduction in mortality among breast cancer patients with *BRCA1/2* mutation.

The variability may affect the decisions of women who are making a decision about whether to receive prophylactic surgery. Knowledge on the efficacy of the different prophylactic strategies is important to both counselors and *BRCA1/2* mutation carriers. This meta-analysis and systematic review was addressed to answer the following research question: What is the effectiveness of each prophylactic surgery implemented in women carrying *BRCA1* or *BRCA2* mutation, in terms of reducing incidence and mortality from breast cancer?

Materials and Methods

Search strategy

To identify all reports of risk-reducing surgery, including PBSO, BPM, and CPM in *BRCA1* or *BRCA2* mutation carriers, we searched the PubMed database using the search terms "breast cancer" and "*BRCA1*" or "*BRCA2*". The search yielded 4,574 studies that were published between August 2014 and September 1999.

Three reviewers independently evaluated titles and abstracts of the identified papers. We also reviewed the references in identified articles for possible inclusions. Only those published studies in English language with full-text articles were included in this meta-analysis. The research did not reveal any additional unpublished studies.

Criteria for inclusion and exclusion

Studies were included in our meta-analysis and systematic review if they met the following criteria: (i) case-control studies or cohort studies, (ii) both case and control subjects were women who carried a deleterious *BRCA1* or *BRCA2* mutation, (iii) studies provided estimates of breast cancer risk reduction or mortality due to prophylactic surgeries, including PBSO, BPM, and CPM, and (iv) relative risk (RR) and the corresponding 95% confidence interval (CI) were reported, or sufficient published data for estimating a RR with 95% CI. Articles reporting only on the utilization of the prophylactic strategies by *BRCA1* or *BRCA2* mutation carriers were excluded. Studies of attitudes, reactions, screening, and chemoprevention practices in *BRCA1/2* mutation carriers were also excluded.

When two or more articles had overlapping study samples, the most recent article based on the largest study population was selected. Of the studies identified here, sample overlaps were noted in the studies of Rebbeck and colleagues (24, 25), Kauff and colleagues (20, 26), Domchek and colleagues (23, 27), and Finkelman and colleagues (21). Finkelman and colleagues (21) was more recent with larger sample size than the other studies, it was chosen for inclusion in the meta-analysis. However, among articles with overlapping study samples, the ones with different subgroup analysis (20) or different research destinations (23) were also included. Although we made every attempt to eliminate redundancy in the data represented in the meta-analysis, we cannot rule out the possibility that a few individuals had participated in more than one study.


Data extraction

Data were carefully extracted from all the eligible studies independently by the investigators. Disagreement was solved by a discussion. The following data were extracted from the included studies if available: first author's name, year of publication, type of study (retrospective or prospective, cohort or case-control), patient source, sample size (number of total subjects with or without prophylactic surgery, number of new PBCs, and number of CBCs), mean age (at prophylactic surgery and at breast cancer), and mean time of follow-up. We then extracted study-specific estimates of RRs (ORs HRs) and the 95% CIs of breast cancer risk, CBC risk or mortality for women with PBSO, BPM, or CPM versus no prophylactic surgery.

Quality assessment

The quality of the studies was assessed using the validated Newcastle-Ottawa Scale (NOS) for nonrandomized studies,

Figure 1.
Flow diagram of articles screened and selected for meta-analysis. BC, breast cancer.



including case-control and cohort studies. Though NOS has been widely utilized, it has not been published in peer-reviewed journals so far. Separate NOS scales were developed for cohort and case-control studies. NOS awards eight points to each cohort study (four for quality of selection, one for comparability, and three for quality of outcome). A study can be awarded a maximum of one star for each point within the selection and outcome categories, and a maximum of two stars can be given for comparability. Besides, NOS also awards eight points to each case-control study (four for quality of selection, one for comparability, and three for quality of exposure). A study can be awarded a maximum of one star for each point within the selection and exposure categories, and a maximum of two stars can be given for comparability. We considered studies with scores of more than 7 as high-quality studies, and those with scores of 7 or less as low-quality studies.

Statistical analysis

We carried out separate meta-analysis in *BRCA1* mutation carriers, *BRCA2* mutation carriers, and among women who carried either *BRCA1* or *BRCA2* mutation (denoted *BRCA1/2*).

We calculated the pooled rate for each outcome (cancer risk or mortality) along with 95% CI. We proceeded to the calculation of pooled effect estimates if there were at least two studies with sufficient data in each outcome of interest. Crude RR with 95% CI was used to assess the association between BPM and breast cancer

risk, and the association between CPM and CBC risk. HR (as published in the original reports) with 95% CI was used as a common measure of the association between PBPSO and breast cancer risk and mortality, and the association between BPM and mortality.

Statistical heterogeneity among studies included in the meta-analysis was assessed using Q statistic (28). Heterogeneity was considered as $P < 0.05$. Two techniques were used to estimate the summary RR estimates. When heterogeneity among studies was absent, the fixed-effects model (the Mantel-Haenszel method; ref. 29) was used to calculate the pooled RRs. Otherwise, a random-effects model (the DerSimonian and Laird method; ref. 30) was selected. Finally, the possibility of publication bias was investigated through Funnel plots, the Begg-Mazumdar adjusted rank correlation test (31) and the Egger regression asymmetry tests (32). $P < 0.05$ was considered statistically significant.

All the P values were two sided. All analyses were conducted using the software Stata version 11.0 (Stata Corporation).

Results

Description of the included studies

Our initial search yielded 4,574 articles, of which we screened the titles and abstracts. Studies (139) were selected for further review. Finally, 15 unique studies were initially selected as

Table 1. Characteristics of 15 studies included in this meta-analysis

Study (ref)	First author	Year	Study design	NOS points	Main study objective
33	Meijers-Heijboer	2001	PC	8	Influence of BPM in B1/2 patients on BC risk
10	Rebbeck	2004	PC	9	Influence of BPM in B1/2 patients on BC risk
17	Eisen	2005	CC	9	Influence of PBSO in B1, B2, or B1/2 patients on BC risk
18	Kramer	2005	PC	7	Influence of PBSO in B1 patients on BC risk
11	van Sprundel	2005	PC	9	Influence of CPM in B1 or B2 patients on CBC risk
19	Chang-Claude	2007	RC	7	Influence of PBSO in B1/2 patients on BC risk
20	Kauff	2008	PC	8	Influence of PBSO in B1 or B2 patients on BC risk
23	Domchek	2010	PC	9	Influence of PS in B1 or B2 patients on BC risk and mortality
34	Skytte	2011	PC	8	Influence of BPM in B1 or B2 patients on BC risk
21	Finkelman	2012	PC	9	Influence of PBSO in B1/2 patients on BC risk
13	Heemskerk-Gerritsen	2013	PC	9	Influence of BPM in B1 or B2 patients on BC risk and mortality
22	Ingham	2013	PC	9	Influence of PS in B1 or B2 patients on BC risk and mortality
16	Evans	2013	PC	9	Influence of CPM in B1/2 patients on CBC risk and mortality
15	Metcalfe	2014	RC	9	Influence of CPM in B1/2 patients on CBC risk and mortality
14	Heemskerk-Gerritsen	2014	PC	9	Influence of CPM in B1 or B2 patients on CBC risk and mortality

Abbreviations: B1, BRCA1; B2, BRCA2; B1/2, BRCA1 or BRCA2; BC, breast cancer; CC, case-control study; PC, prospective cohort study; RC, retrospective cohort study.

potentially appropriate for meta-analysis inclusion. Our search strategy is presented in Fig. 1.

The details of eligible studies are summarized in Tables 1 and 2. As can be seen in this summary, the studies that formed the basis for this meta-analysis included prospective cohort studies, retrospective cohort studies, and case-control studies. Limitations of the currently available data regarding prophylactic surgery in *BRCA1* or *BRCA2* mutation carriers include variable study designs, small sample size for some studies, and different durations of post-surgery follow-up times. We have summarized the results of meta-analysis when two or more eligible studies could be meta-analyzed, as well as the individual articles where only a single eligible study was available.

Thirteen studies had a quality score higher than 7 points, and 2 studies had a quality score equal to 7 points (Table 1).

Prophylactic surgery and breast cancer risk

PBSO and breast cancer risk. Three nonoverlapping studies (17, 19, 21) investigated the risk of breast cancer in *BRCA1/2*

mutation carriers who were treated with PBSO relative to *BRCA1/2* mutation carriers who did not receive any prophylactic surgery. In total, 7,323 women with *BRCA1/2* mutation were included in the meta-analysis. PBSO was associated with a decreased risk of breast cancer in *BRCA1/2* mutation carriers (summary RR, 0.552; 95% CI, 0.448–0.682; Table S1, Figure 2A). Four nonoverlapping studies (17–19, 21) estimated the risk reduction associated with PBSO for breast cancer in *BRCA1* mutation carriers, giving a summary RR estimate of 0.47 (95% CI, 0.348–0.636; Table S1, Figure 2B). And 3 non-overlapping studies (17, 19, 20) estimated the risk reduction associated with PBSO for breast cancer in *BRCA2* mutation carriers, giving a summary RR estimate of 0.468 (95% CI, 0.263–0.835; Table S1, Figure 2C).

BPM and breast cancer risk. Six nonoverlapping studies (10, 13, 22, 23, 33, 34), which included 2,555 participants, estimated the risk of breast cancer in *BRCA1/2* mutation carriers treated with BPM relative to *BRCA1/2* mutation carriers who did not receive any prophylactic surgery. Compared with controls, the occurrence

Table 2. Characteristics of patients of individual studies included in this meta-analysis

Study (ref)	First author	Year	Patients source	No. with/without PS			Mean follow-up PS/no PS	Mean age at BC (y) PS/no PS	Mean age at PS (y)
				BRCA1/2	BRCA1	BRCA2			
33	Meijers-Heijboer	2001	SIS	76/63	NR	NR	B1/2: 2.9/3.0	39.8	B1/2: 37.7
10	Rebbeck	2004	NAEMC	59/305	NR	NR	5.5/6.7	B1/2: 35.3/41.3	B1/2: 35.4
17	Eisen	2005	IMC	166/3139	129/2341	36/786	Max 15	B1: 38.9; B2: 40.9	NR
18	Kramer	2005	NAMC	NR	33/65	NR	Mean 16.5 11,105 PYO	B1: 47.4/46.5	NR
11	van Sprundel	2005	TIS	79/69	60/55	19/14	7.4/10.5	NR	41.9
19	Chang-Claude	2007	EMC	55/1601	NR	NR	65,675 PY	B1/2: 50.1	NR
20	Kauff	2008	IMC	509/283	325/173	184/140	3.2	B1: 49.8/44.0; B2: 52.5/53.0	B1: 46.2; B2: 48.8
23	Domchek	2010	NAEMC	75/585	43/372	32/213	3.1	NR	B1/2: 37.9; B1: 36.7; B2: 39.4
34	Skytte	2011	DMC	96/211	67/134	29/77	Max > 7	NR	B1/2: 37.1
21	Finkelman	2012	IMC	763/1599	NR	NR	B1/2: 6.5/4.5	B1/2: 47.9/42.9	B1/2: 45.9
13	Heemskerk-Gerritsen	2013	SIS	212/358	156/249	56/109	1379/2037PYO	B1/2: 43	B1/2: 35
22	Ingham	2013	SIS	58/457	29/219	29/238	Median 13.3	NR	NR
16	Evans	2013	SIS	43/473	NR	NR	Median 9.7/8.6	NR	NR
15	Metcalfe	2014	IMC	181/209	NR	NR	13	NR	NR
14	Heemskerk-Gerritsen	2014	IMC	242/376	193/296	49/80	9.6/7.4	Median 42	Median 42

Abbreviations: B1, BRCA1; B2, BRCA2; B1/2, BRCA1 or BRCA2; BC, breast cancer; DMC, Denmark multicenter cohort study; EMC, European multicenter cohort study; IMC, International multicenter cohort study; NAEMC, North American and European multicenter cohort study; NAMC, North American multicenter cohort study; NOS, Newcastle-Ottawa Scale; NR, not reported; PS, prophylactic surgery; PY, person-years; PYO, person-years of observation; Ref, reference; SIS, single institution study; TIS, two institutions study.






Figure 2. Meta-analysis of PBSO and breast cancer risk in *BRCA1* or *BRCA2* mutation carriers. **A**, PBSO and breast cancer risk in *BRCA1/2* mutation carriers. **B**, PBSO and breast cancer risk in *BRCA1* mutation carriers. **C**, PBSO and breast cancer risk in *BRCA2* mutation carriers. The width of the horizontal line represents the 95% CI of the individual study, and the square proportional represents the weight of each study. The weight was calculated by the sample size of each individual study, and was presented by the percentage of total. The diamond represents the pooled RR and 95% CI. BC, breast cancer.

Downloaded from <http://aacrjournals.org/clinccancerres/article-pdf/22/15/3971/2963837/3971.pdf> by guest on 26 May 2022




Figure 3. Meta-analysis of PM and breast cancer risk in *BRCA1/2* mutation carriers. **A**, BPM and breast cancer risk in *BRCA1/2* mutation carriers. **B**, CPM and CBC risk in *BRCA1/2* mutation carriers. The width of the horizontal line represents the 95% CI of the individual study, and the square proportional represents the weight of each study. The weight was calculated by the sample size of each individual study, and was presented by percentage of total. The diamond represents the pooled RR and 95% CI. BC, breast cancer.

of post-BPM breast cancer in cases corresponds to a RR of 0.114 (95% CI, 0.041–0.317), confirming a substantial and statistically significant reduction in breast cancer risk after BPM in *BRCA1/2* mutation carriers (Table S2, Figure 3A). Based on data from 4 nonoverlapping studies (13, 22, 23, 34), which included 1,269 participants, BPM significantly decreased the incidence of breast cancer (summary RR, 0.134; 95% CI, 0.019–0.937) in *BRCA1* mutation carriers (Table S2). Finally, based on data from the same 4 nonoverlapping studies (13, 22, 23, 34), which included 783 participants, BPM significantly decreased the incidence of breast cancer (summary RR, 0.183; 95% CI, 0.072–0.468) in *BRCA2* mutation carriers (Table S2).

CPM and CBC risk. For the analyses of CPM and CBC risk in *BRCA1/2* mutation carriers, 4 nonoverlapping studies (11, 14–16)

were included, which included 1,672 participants. CPM significantly decreased the incidence of CBC in *BRCA1/2* mutation carriers (summary RR, 0.072; 95% CI, 0.035–0.148; Table S3, Figure 3B). No study estimated the risk reduction associated with CPM separately in *BRCA1* and *BRCA2* mutation carriers.

Prophylactic surgery and mortality

PBSO and mortality. Mortality reduction following PBSO was estimated separately in different scenarios incorporating mutation type (*BRCA1* or *BRCA2*) and breast cancer history (prior history of breast cancer or none).

PBSO and mortality in those with no prior history of breast cancer. Two nonoverlapping studies (22, 23) were included in the meta-analysis of PBSO and mortality in *BRCA1/2* mutation carriers with

Table 3. PS and mortality in *BRCA1/2* mutation carriers

First author	Year	Study design	All-cause mortality RR (95% CI)	BC-specific mortality RR (95% CI)
PBSO in patients without prior history of BC				
Domchek	2010	PC	HR 0.45 (0.21–0.95)	HR 0.27 (0.05–1.33)
Ingham	2013	PC	HR 0.22 (0.08–0.61)	NA
Summary HRs for all studies			HR 0.349 (0.190–0.639)	
PBSO in patients with prior history of BC				
van Sprundel	2005	PC	HR 0.23 (0.07–0.78)	HR 0.28 (0.07–1.11)
Domchek	2010	PC	HR 0.3 (0.17–0.52)	HR 0.35 (0.19–0.67)
Evans	2013	PC	HR 0.46 (0.27–0.78)	NA
Metcalfe	2014	RC	HR 0.67 (0.38–1.17)	NA
Summary HRs for all studies			HR 0.432 (0.318–0.588)	HR 0.337 (0.190–0.598)
BPM in women without BC				
Ingham SL	2013	PC	HR 0.25 (0.03–1.81)	HR 0.29 (0.03–2.61)
Heemskerck-Gerritsen	2013	PC	HR 0.20 (0.02–1.68)	NA
Summary HRs for all studies			HR 0.226 (0.05–1.016)	
CPM in patients with UBC				
van Sprundel	2005	PC	HR 0.35 (0.09–1.39)	NA
Evans	2013	PC	HR 0.48 (0.19–1.14)	NA
Metcalfe	2014	RC	HR 0.58 (0.34–0.97)	10Y HR 0.65 (0.34–1.22) 20Y HR 0.52 (0.29–0.93)
Heemskerck-Gerritsen	2014	PC	HR 0.49 (0.29–0.82)	NA
Summary RRs for all studies			HR 0.512 (0.368–0.714)	
Both PBSO + CPM in patients with UBC				
van Sprundel	2005	PC	HR 0.12 (0.03–0.46)	HR 0.16 (0.04–0.61)
Evans	2013	PC	HR 0.16 (0.06–0.44)	NA
Summary HRs for all studies			HR 0.145 (0.065–0.324)	

Abbreviations: BC, breast cancer; NA, not applicable; PC, prospective cohort study; RC, retrospective cohort study.

no prior history of breast cancer. PBSO was associated with significantly lower all-cause mortality (summary HR, 0.349; 95% CI, 0.190–0.639) (Table 3 and Figure 4A). One study carried out by Domchek and colleagues (23) analyzed the association stratified by mutation status. It reported that all-cause mortality in *BRCA1* mutation carriers was not statistically significant (HR, 0.52; 95% CI, 0.24–1.14). No study researched the relationship between mortality and PBSO in *BRCA2* mutation carriers without prior history of breast cancer.

Besides, Domchek and colleagues (23) demonstrated that breast cancer-specific mortality reduction was not statistically significant in *BRCA1/2* mutation carriers with no prior breast cancer (HR, 0.27; 95% CI, 0.05–1.33), neither in *BRCA1* mutation carriers (HR, 0.30; 95% CI, 0.06–1.53).

PBSO and mortality in those with prior history of breast cancer. Four nonoverlapping studies (11, 15, 16, 23) were included in the meta-analysis of PBSO and mortality in *BRCA1/2* mutation carriers with prior breast cancer. PBSO was associated with a significantly lower all-cause mortality in *BRCA1/2* mutation carriers (summary HR, 0.432; 95% CI, 0.318–0.588; Table 3, Figure 4B), as well as breast cancer-specific mortality (summary HR, 0.337; 95% CI, 0.190–0.598; Table 3).

When analyzed by mutation status, Domchek and colleagues (23) demonstrated that PBSO was associated with a significantly lower all-cause mortality (HR, 0.26; 95% CI, 0.13–0.52) and breast cancer-specific mortality (HR, 0.27; 95% CI, 0.12–0.58) in *BRCA1* mutation carriers. With fewer participants and fewer events, all-cause mortality (HR, 0.45; 95% CI, 0.17–1.16) and breast cancer-specific mortality (HR, 0.87; 95% CI, 0.32–2.37) in *BRCA2* mutation carriers was not reduced statistically significantly.

BPM and mortality. Two eligible nonoverlapping articles (13, 22) examined the association of BPM and mortality among *BRCA1/2*

mutation carriers with no prior history of cancer. BPM was not significantly associated with reduced all-cause mortality (summary HR, 0.226; 95% CI, 0.05–1.016; Table 3, Figure 5A). Heemskerck-Gerritsen and colleagues (13) found that breast cancer-specific mortality was also not significantly reduced, giving a HR of 0.29 (95% CI, 0.03–2.61).

CPM and mortality. Four nonoverlapping articles (11, 14–16) were eligible examining the association of CPM and all-cause mortality among *BRCA1/2* mutation carriers with unilateral breast cancer (UBC). All-cause mortality was significantly lower for patients with CPM than for those without CPM (summary HR, 0.512; 95% CI, 0.368–0.714; Table 3, Figure 5B). Besides, a study carried out by van Sprundel and colleagues (11) showed that breast cancer-specific survival was not significantly better in the CPM group (log rank, $P = 0.11$). Another study carried out by Metcalfe and colleagues (15) showed that CPM was significantly associated with reduced breast cancer-specific mortality for the entire 20-year study period of follow-up (HR, 0.52; 95% CI, 0.29–0.93), but not significantly associated for the first 10 years of follow-up (HR, 0.65; 95% CI, 0.34–1.22).


Obviously, the combination of PBSO and CPM gave the best overall survival. Having opted for both CPM and PBSO resulted in a significantly better survival than surveillance only (all-cause mortality summary HR, 0.145; 95% CI, 0.065–0.324), based on data from two eligible articles (11, 16); Table 3).

Publication bias. We found no evidence of publication bias in any analyses using Begg or Egger tests (all $P > 0.05$).

Discussion

This is, to the best of our knowledge, the first study that systematically investigated the most appropriate prophylactic surgery of breast cancer in *BRCA1/2* mutation carriers. We have

A Study



B Study





Figure 4. Meta-analysis of PBSO and all-cause mortality in *BRCA1/2* mutation carriers, **A**, PBSO and all-cause mortality in *BRCA1/2* mutation carriers with no prior history of breast cancer. **B**, PBSO and all-cause mortality in *BRCA1/2* mutation carriers with prior history of breast cancer. The width of the horizontal line represents the 95% CI of the individual study, and the square proportional represents the weight of each study. The weight was calculated by the sample size of each individual study, and was presented by the percentage of total. The diamond represents the pooled RR and 95% CI. BC, breast cancer.

summarized the evidence for prophylactic surgeries of breast cancer risk and mortality in women who have inherited *BRCA1* or *BRCA2* mutations.

The results of this meta-analysis suggest a 45% reduction in breast cancer risk, and a 65% reduction in all-cause mortality associated with PBSO in women who carry *BRCA1/2* mutation with no prior history of breast cancer. And PBSO was associated with a 57% reduction in all-cause mortality in breast cancer patients. All the available data may demonstrate the utility of PBSO in this population of patients. However, previous studies reported that 90% of invasive breast cancers found in *BRCA1* mutation carriers were estrogen receptor (ER) and progesterone receptor (PR) negative (35–37). And tumors associated with *BRCA2* mutations tend to be ER and PR positive (38). So, it is critical to understand how risk reduction may differ by gene. The prospective cohort study carried out by Kauff and colleagues (20) demonstrated that PBSO may be associated with a greater reduction in breast cancer risk in *BRCA2* mutation carriers than in *BRCA1* mutation carriers. However, the retrospective cohort study (19) and case-control study (17) did not

observe this difference. Similarly, we did not observe this difference in our meta-analysis. To date, limited studies have been reported on the survival benefit of PBSO separately by gene; no meta-analysis could be performed. Domchek and colleagues (23) demonstrated in a prospective cohort study that PBSO was associated with a significantly lower all-cause mortality and breast cancer-specific mortality in *BRCA1* mutation carriers, but not significantly in *BRCA2* mutation carriers with prior history of breast cancer. Meanwhile, they found that all-cause mortality in *BRCA1* mutation carriers with no prior history of breast cancer was not reduced significantly. It is supposed that differences in study design, small sample size, and short period of follow-up time may influence the inferences we can make about the differences in risk reduction associated with PBSO in *BRCA1* versus *BRCA2* mutation carriers. And others suggested that PBSO might inhibit breast cancer growth in *BRCA1* mutation carriers at tumorigenesis: growth of ER- and PR-negative cells might be indirectly induced paracrine signals from ER- and PR-positive cells that are influenced by estrogen and progesterone. It is also supposed that

**Figure 5.**

Meta-analysis of PM and all-cause mortality in *BRCA1/2* mutation carriers. **A**, BPM and all-cause mortality in *BRCA1/2* mutation carriers with no breast cancer. **B**, CPM and all-cause mortality in *BRCA1/2* mutation carriers with UBC. The width of the horizontal line represents the 95% CI of the individual study, and the square proportional represents the weight of each study. The weight was calculated by the sample size of each individual study, and was presented by the percentage of total. The diamond represents the pooled RR and 95% CI. BC, breast cancer.

PBSO exerts more than just an antiestrogenic effect. Definitely, the mechanism of action of PBSO in *BRCA1* mutation carriers is unclear and should be investigated further.

PM is considered to be the most effective strategy for reducing breast cancer risk. The results of this meta-analysis suggested that BPM was associated with a 90% reduction in breast cancer risk, and CPM was associated with a 93% reduction in CBC risk. It is clear that PM does not completely eliminate the breast cancer risk. There is still a residual risk of breast cancer after PM in *BRCA1/2* mutation carriers. The potential mechanism requires further research. In addition, the results indicated that all-cause mortality rates were reduced by BPM, although significant survival benefits could not be claimed yet. However, CPM was found to be significantly associated with improved overall survival in *BRCA1/2* mutation carriers with a history of UBC. Of note, CBCs were mostly diagnosed at a more favorable stage than PBCs, that is more DCIS, smaller tumor size and more node-negative breast cancer, which may be the result of accurate surveillance after PBC (14). Thus, the survival benefit of CPM cannot completely

be explained by the prevention of CBC-associated deaths. However, despite a relatively lower CBC stage, it is suggested that survival of sporadic bilateral breast cancer is worse than survival of UBC patients (39, 40). Whether this difference could apply for *BRCA1/2* mutation carriers is not clear yet, and should be investigated further.

All in all, the meta-analysis and systematic review provide an up-to-date analysis of the advantages of prophylactic surgeries in *BRCA1/2* mutation carriers. However, selecting the most appropriate prophylactic strategy is not a straightforward task. Prophylactic surgeries may ensure a very high protection from breast cancer, but are associated with a number of disadvantages of invasiveness, nonreversibility, and surgical morbidity. PBSO could cause menopause with its attendant symptoms, increase in heart disease and osteoporosis risk, and for some women a loss of sexuality and gender identity (41–43). PM may even have a greater impact psychologically than PBSO because it affects body image. Parting with a healthy breast (or two) to prevent a probability is very difficult, which may result

in anxiety, lack of self-esteem, and possibly depression. However, the decision to undergo prophylactic surgery is an individual and personal choice that a woman has to make together with her doctor.

In a meta-analysis of the literature, we must always bear in mind that results are based on the findings of completed studies. As a result, there are some limitations in the present meta-analysis. First, to date, comparative data on the advantage of prophylactic surgery among *BRCA1/2* mutation carriers are limited. Limitations of the currently available data regarding prophylactic surgery in *BRCA1/2* mutation carriers include variable study designs, small sample size for some studies, variable patients' age, and so on. Of note, a case-control design study was included in the summary estimates, which yielded ORs rather than HRs. Although ORs may slightly overestimate the risk reduction associated with PBSO, the annual incidence of breast cancer in *BRCA1/2* mutation carriers is no more than 2% to 4%, with the result that ORs are likely to be similar to HRs in this setting. Second, though HRs of included studies are all adjusted by acknowledged relevant factors to ensure relative reliability, some reported studies use different adjustments for potential confounder variables. The inconsistent use of adjustment and matching factors may further limit the comparability of studies, and may have resulted in varying levels of confounding across studies. In addition, crude RR with 95% CI was used to assess the association between BPM and breast cancer risk, and the association between CPM and CBC risk. Because of the insufficient information provided by the original articles, it is impossible to calculate weighted pooled estimates. Moreover, no adjusted RR was presented in most of these articles. As a result, we could only calculate crude RR through data extracted from these articles. A third limitation concerns the small numbers of *BRCA2* mutation carriers in most studies investigating the survival benefit of prophylactic surgery, so that analyzing the data separately for *BRCA1* and *BRCA2* mutation carriers was not possible. Fourth, the age at prophylactic surgery and the follow-up periods for participants have differed between studies eligible in the meta-analysis. Thus, the effect of age at prophylactic surgery on breast cancer risk and mortality reduction remains unresolved. And for short post-surgery follow-up times in some studies, a delay in the observed benefit of prophylactic surgery is to be expected. Besides, to obtain sufficient evidence and detect the real associations, a longer follow-up period is better. Though the results were acquired through statistical analysis and differences were detected statistically, a short period of follow-up time might cause low statistical power. Additionally, in most of the studies included in this meta-analysis, the proportion of those who had PS compared with those without PS was so small, which might lead to unreliable RR value. As a limitation, the method of meta-analysis could not avoid such disadvantages of initial studies completely. Nevertheless, we therefore took advantages of meta-analysis to draw more reliable conclusions comparing individual studies. Furthermore, a potential selection bias of patients who did and did not undergo risk-reduction surgery might generate influence to the conclusions. However, due to the limited initial data of each

study, it is insufficient to evaluate the baseline characteristics of patients who did and did not undergo risk-reduction surgery. Consequently, a conservative attitude should be held towards the results. Accordingly, more case-control or cohort studies of high quality with longer follow-up period and more details of basic information are required in the future, so as to draw more accurate conclusions. Finally, ideally, the evaluation of prophylactic surgery on cancer risk and mortality reduction would involve a randomized trial design. However, there are no randomized controlled trials concerned with the demonstration of the potential benefits or harms of prophylactic surgery currently, for that it is accepted in the field that a randomized approach would neither be acceptable nor ethical.

Conclusions

In conclusion, options to reduce the high breast cancer incidence and mortality risk include PBSO and PM (BPM and CPM). The summary risk reduction estimates presented in our meta-analysis confirm that *BRCA1/2* mutation carriers who have been treated with prophylactic surgery have a substantially reduced risk of breast cancer and mortality. This meta-analysis and systematic review could serve as a helpful guide for clinicians during the discussion with their patients before the final prophylactic surgical decision is made. However, further prospective studies with larger sample size and longer follow-up periods are still required to get a more precise estimation of the benefits and potential harms of prophylactic surgeries among *BRCA1* or *BRCA2* mutation carriers.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: X. Li, C. Liu, Z. Xu, B. Yu, T. Xu, H. Cai
Development of methodology: R. You, X. Wang, J. Zhou, H. Cai, Q. Zou
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): X. Li, C. Liu
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): X. Li, B. Yu
Writing, review, and/or revision of the manuscript: X. Li, R. You, X. Wang, C. Liu, B. Yu, H. Cai
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Cai, Q. Zou
Study supervision: Z. Xu, T. Xu, H. Cai, Q. Zou

Grant Support

This work was supported by the Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University (ZQ 201301 and ZQ 201302), Nanjing, China, and the Nanjing Science and Technology Plan Project (201201087).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 21, 2015; revised February 1, 2016; accepted February 6, 2016; published OnlineFirst March 15, 2016.

References

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003; 72:1117-30.
2. Chen S, Parmigiani G. Meta-analysis of *BRCA1* and *BRCA2* penetrance. *J Clin Oncol* 2007;25:1329-33.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in *BRCA1*-mutation carriers. Breast Cancer Linkage Consortium. *Lancet* 1994;343:692-5.

4. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of *BRCA1*. *Lancet* 1998;351:316–21.
5. Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of *BRCA2*. *J Clin Oncol* 1999;17:3396–402.
6. van der Kolk DM, de Bock GH, Leege BK, Schaapveld M, Mourits MJ, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in *BRCA1* and *BRCA2* families: high cancer incidence at older age. *Breast Cancer Res Treat* 2010;124:643–51.
7. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for *BRCA1* and *BRCA2* mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013;105:812–22.
8. Bougie O, Weberpals JI. Clinical Considerations of *BRCA1*- and *BRCA2*-Mutation Carriers: A Review. *Int J Surg Oncol* 2011;2011:374012.
9. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77–84.
10. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in *BRCA1* and *BRCA2* mutation carriers: the PROSE study group. *J Clin Oncol* 2004;22:1055–62.
11. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in *BRCA1* or *BRCA2* mutation carriers. *Br J Cancer* 2005;93:287–92.
12. Kiely BE, Jenkins MA, McKinley JM, Friedlander ML, Weideman P, Milne RL, et al. Contralateral risk-reducing mastectomy in *BRCA1* and *BRCA2* mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). *Breast Cancer Res Treat* 2010;120:715–23.
13. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy *BRCA1* and *BRCA2* mutation carriers: a prospective analysis. *Ann Oncol* 2013;24:2029–35.
14. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in *BRCA1/2* mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer* 2015;136:668–77.
15. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of *BRCA1* and *BRCA2* mutations: retrospective analysis. *BMJ* 2014;348:g226.
16. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with *BRCA1/2*-associated breast cancer. *Breast Cancer Res Treat* 2013;140:135–42.
17. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in *BRCA1* and *BRCA2* mutation carriers: an international case-control study. *J Clin Oncol* 2005;23:7491–6.
18. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struwing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of *BRCA1* mutation carriers. *J Clin Oncol* 2005;23:8629–35.
19. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, et al. Age at menarche and menopause and breast cancer risk in the International *BRCA1/2* carrier cohort study. *Cancer Epidemiol Biomarkers Prev* 2007;16:740–6.
20. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of *BRCA1*- and *BRCA2*-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol* 2008;26:1331–7.
21. Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, et al. Breast and ovarian cancer risk and risk reduction in Jewish *BRCA1/2* mutation carriers. *J Clin Oncol* 2012;30:1321–8.
22. Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, et al. Risk-reducing surgery increases survival in *BRCA1/2* mutation carriers unaffected at time of family referral. *Breast Cancer Res Treat* 2013;142:611–8.
23. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in *BRCA1* or *BRCA2* mutation carriers with cancer risk and mortality. *JAMA* 2010;304:967–75.
24. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in *BRCA1* mutation carriers. *J Natl Cancer Inst* 1999;91:1475–9.
25. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of *BRCA1* or *BRCA2* mutations. *N Engl J Med* 2002;346:1616–22.
26. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2002;346:1609–15.
27. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in *BRCA1* and *BRCA2* mutation carriers: a prospective cohort study. *Lancet Oncol* 2006;7:223–9.
28. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med* 1997;127:820–6.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22:719–48.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
33. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluijmers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2001;345:159–64.
34. Skytte AB, Cruger D, Gerster M, Laenholm AV, Lang C, Brøndum-Nielsen K, et al. Breast cancer after bilateral risk-reducing mastectomy. *Clin Genet* 2011;79:431–7.
35. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, et al. Tumour biological features of *BRCA1*-induced breast and ovarian cancer. *Eur J Cancer* 1997;33:362–71.
36. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. *BRCA*-associated breast cancer in young women. *J Clin Oncol* 1998;16:1642–9.
37. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset *BRCA1* breast-cancer patients. Institut Curie Breast Cancer Group. *Lancet* 1998;352:541.
38. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluijmers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from *BRCA2*-, *BRCA1*- and non-*BRCA1/2* families as compared to sporadic breast cancer cases. *Eur J Cancer* 2007;43:867–876.
39. Schaapveld M, Visser O, Louwman WJ, Willemsse PH, de Vries EG, van der Graaf WT, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. *Breast Cancer Res Treat* 2008;110:189–97.
40. Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. *J Clin Oncol* 2012;30:3478–85.
41. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdóttir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. *J Clin Oncol* 2005;23:6890–8.
42. Hollowell N, Mackay J, Richards M, Gore M, Jacobs I. High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: a descriptive study. *Genet Test* 2004;8:148–56.
43. Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. *Br J Cancer* 2011;105:22–7.